LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: 3-YEAR INTERIM RESULTS FROM THE ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY

Jasmina Kalabic    

Conference
UEG Week 2019


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing